You are here
AstraZeneca buys US biotech firm CinCor
By AFP - Jan 09,2023 - Last updated at Jan 09,2023
LONDON — Anglo-Swedish pharmaceuticals giant AstraZeneca on Monday agreed to buy US biotech company CinCor for $1.8 billion, expanding further into the field of heart and kidney drugs.
The takeover marks the latest push by Astra Chief Executive Pascal Soriot to bolster the COVID vaccine maker's pipeline of new products.
Massachusetts-based CinCor focuses on developing treatments for hypertension and chronic kidney disease.
Since taking the helm at AstraZeneca in 2012, Frenchman Soriot has expanded the company into lucrative cancer therapies.
The group completed a blockbuster takeover of Alexion for $39 billion in 2021, giving it more heft in areas such as treating blood disorders.
Related Articles
LONDON — Anglo-Swedish pharmaceuticals giant AstraZeneca on Thursday agreed to buy French biotech specialist Amolyt Pharma for about $1 bill
BRUSSELS — The European Union on Wednesday asked a Belgian court to impose penalties running to millions of euros per day on AstraZeneca for
OSLO — A health worker in Norway has died of a brain haemorrhage after receiving the AstraZeneca anti-COVID vaccine, though no direct link t
Opinion
Nov 11, 2024
Nov 11, 2024
- Popular
- Rated
- Commented
Nov 11, 2024
Nov 11, 2024
Nov 11, 2024
Newsletter
Get top stories and blog posts emailed to you each day.
